

Company name: Minapharm pharmaceutical

an audited financial indicator for the financial year period ended on 30/09/2023.

Currency: EGP

(The form should include the company's comment on the results of the business with the most important factors that led to profit/loss)

First, the financial indicators

(A) statement of profit or loss for the year/period ended on 30/09/2023

	Current period	comparative financial statements	change%
Revenue/sales	1,883,360,300	1,697,852,453	11%
Total profit (loss)	605,746,245	560,527,253	8%
The ratio of total profit to revenue/sales	0.32	0.33	-3%
Net profit (loss) before tax from continuing activities	88,726,229	277,346,488	-68%
Net profit (loss) before tax from non-continuing activities (if any)	-	-	0%
Net profit (loss) after tax	62,868,944	214,094,470	-71%
Earnings / (losses) per share (EPS)	5.98	17.41	-66%
Diluted share of profit / loss (if any)	-	-	0%

شركة مينافارم للأدوية والصناعات الكيماوية
ط ٢ ش. البرديس من أسماء فهمي
خلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet www.minapharm.com

(B) Statement of financial position in 30/09/2023

	Current period	comparative financial year (previous Year)	change%
Net working capital	(631,760,217)	129,580,072	-588%
Owner's equity	1,035,825,756	1,028,693,497	1%
Paid capital	122,934,400	122,934,400	0%
Reserves	291,996,136	291,996,136	0%
Retained earnings	627,652,811	469,295,026	34%
The profit (loss) of the period	62,868,944	214,094,470	-71%
Other			
Treasury Shares	69,626,535	69,626,535	0%

(C) cash flow statement for the year 30/09/2023

	Current period	comparative financial statements	Change%
Cash flows from (to) operating activities	251,133,923	75,102,863	234%
Cash flows from (to) investment activities	916,964,235-	-584,252,591	57%
Cash flows from (to) financing activities	849,542,643	553,234,289	54%

Second: Material events that have occurred since the date of the financial results till now and should be disclosed.

None

شركة مينا فارم للأدوية والصناعات الكيماوية
إط ش. البرديس من أسماء فهمي
خلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet www.minapharm.com

Agree

We acknowledge that the above-mentioned statements are extracted from the Company's financial statements issued by the Board of Directors held on 13 /11/2023 and have not yet issued the auditor's report and we undertake to promptly disclose to FRA and EGX if any change in these statements as soon as it occurs until the submission of the signed financial statements which we undertake to send immediately after Issue the auditor/auditor's report before the beginning of the trading session of the following day according to the date recorded in the auditor's report, which we expect to be a " clean" report .


(if amended, please state the reasons given in the annex (No. 2)).

Investor relations officer



Date
14/11/2023

Chairman



The company's stamp.

شركة مينافارم للأدوية والصناعات الكيماوية
أط ش. البرديس من أسماء فهمى
خلف الرقابة الإدارية - أرض الجولف

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet www.minapharm.com